

## Supplementary material: Figures S1, S2 and Table S1

Figure S1: Kaplan-Meier curves of overall survival and metastasis-free survival for rMBC patients with HR+ HER2+ tumours (N=89)




Figure S2: Kaplan-Meier curves of overall survival and metastasis-free survival for rMBC patients with HR- HER2+ tumours (N=60)




Table S1: Kaplan-Meier estimates of stage-specific survival outcomes of rMBC patients for each biological subtype

	N	10-year OS	N	5-year MFS
<b>HR+ HER2-</b>				
Stage I	56	37.2%	56	51.8%
Stage IIA	91	50.8%	91	57.1%
Stage IIB	71	35.3%	71	49.3%
Stage III	153	29.6%	153	37.3%
<b>HR+ HER2+</b>				
Stage I	14	35.7%	14	14.3%
Stage IIA	15	26.7%	16	37.5%
Stage IIB	15	42.1%	15	40.0%
Stage III	44	14.0%	44	34.1%
<b>HR- HER2+</b>				
Stage I	11	31.2%	11	18.2%
Stage IIA	11	11.4%	12	25.0%
Stage IIB	5	50.0%	5	20.0%
Stage III	32	15.6%	32	3.1%
<b>TNBC</b>				
Stage I	8	37.5%	8	62.5%
Stage IIA	19	0.0%	19	15.8%
Stage IIB	20	11.7%	20	0.0%
Stage III	26	7.7%	26	11.5%